Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus

By Kanazawa I.   Yamaguchi T.   Yano S.   Yamamoto M.   Yamauchi M.   Kurioka S.   Sugimoto T.  

Osteoporosis International, Vol. 21, Iss. 12, 2010-12 ,pp. : 2013-2018

Springer Publishing Company

Access to resources Recommend Favorite

General effect on high-risk persons when general practitioners are trained in intensive treatment of type 2 diabetes

By Rasmussen Signe   Glumer Charlotte   Sandbaek Annelli   Lauritzen Torsten   Borch-Johnsen Knut  

Scandinavian Journal of Primary Health Care, Vol. 26, Iss. 3, 2008-01 ,pp. : 166-173

Informa Healthcare

Access to resources Recommend Favorite

Association between type 2 diabetes, curative treatment and survival in men with intermediate‐ and high‐risk localized prostate cancer

By  

BJU INTERNATIONAL, Vol. 121, Iss. 2, 2018-02 ,pp. : 209-216

John Wiley & Sons Inc

Access to resources Recommend Favorite

Type 2 diabetes, thiazolidinediones, and cardiovascular risk

By Taylor Clare   Hobbs FD Richard  

British Journal of General Practice, Vol. 59, Iss. 564, 2009-07 ,pp. : 520-524

Royal College of General Practitioners

Access to resources Recommend Favorite

Xultophy: combination therapy for the treatment of type 2 diabetes

By  

PRESCRIBER, Vol. 26, Iss. 17, 2015-09 ,pp. : 32-34

John Wiley & Sons Inc

Access to resources Recommend Favorite